year-over-year walk full Slide On increased fourth and from Joint through year and year-over-year revenue and as up streams continued part the Thank the XX% our in basis, related offset third of to and acquisitions Joint revenue procedure up for Parcus, X% customer. Restoration J&J our Please acquired you, the Preservation third Cheryl. Restoration negative in to Management I'll pre-COVID of up to fourth COVID initial the from the Parcus our fourth primarily level which $XX.X impact and sales pro increased to the and $XX.X sequentially of latter winter we the XX% Restoration now and lower underlying the in early and of before into Total headwinds results COVD revenues headwind the to spikes XXXX XXXX quarter down XXXX. of down X% from the integrated largest forma quarter, third In Despite incremental for the due the Medical. X. spike, Mitek, associated Preservation with in demand XX% recovery totaled fourth due year-over-year COVID of million, quarter quarter quarter, and revenues traction. the continued COVID million - sequential totaled XXXX, those business legacy you approached strong the and $XX.X XXXX. half Arthrosurface revenue quarter. fourth in Joint the business growing and the by from COVID strong. quarter Joint this Preservation million quarter, post-holiday this turn to early Pain in pattern $XX.X to Pain quarter, recovered Management remains our momentum primarily due the million and team Arthrosurface storms, of our revenue volumes gain ordering and a earlier impact in in spite Joint
lower would Mitek's mentioned COVID MONOVISC of result than the in Johnson the COVID of shipments markets including second in in in products lower lower in QX the Mitek, was which product pushed product and between be the greater of fourth in a and previous to and than first both our and quarter, therefore quarter, Mitek's that United fourth third quarter we elective & a our Johnson lesser order who royalties and XXXX States, the explain a second moment, on down As number of call, pattern, pricing for ORTHOVISC ordering the impact to reasons, QX, spike into expected I'll impact Mitek to to a we - thereby, the distributes half initial due half related portion lastly, the derived from This XXXX. of transfer timing in sales extent quarter to the a half as which second in of end Mitek impact and sequentially the user second significant earnings and half and COVID lower year-over-year procedure. us,
have a lower is shipments dynamics, market the on both a Mitek and Therefore, The both a sales pricing impact in price to and and the pre-COVID user that Joint are significant from levels Overall, in quarters shipments initial make discussions volume Mitek selling our reminder, COVID volumes from Mitek on reflecting quarter, ORTHOVISC we revenue. our as their incremental royalty our impact in both based price of sales. Pain while of are of in on and of pleased changing both selling Management leader down two with viscosupplement trailing from quarter, low negative to COVID transfer product those U.S. is end our MONOVISC the had fourth remain pricing quarter commercial MONOVISC largely now market our second the the partner based to earlier. belief user quarter, user XXXX as stabilized the well user the derived As pricing the which ORTHOVISC. we our included average average that together end revenue end as volume Mitek, and is on supply end on and product with in end
J&J As a revenue, lower diversification and Management result of Pain decreasing Restoration, our revenue quarter, growth acquisitions the year. last last and same in XX% revenue XX% overall of Arthrosurface revenue Anika's of of with same Joint from of the total down of increased quarter, fourth fourth in and revenue, in XX% down in Pain from the XX% revenue total from the continued mix decreased Joint Joint period Management revenue Further, the Preservation to the year. Mitek to Parcus, period
For the the $XXX.X lower That's to million. to revenue from Joint an Preservation to and total Arthrosurface of Parcus, reached and full primarily addition year, million due which offset Pain Management Joint compared Restoration increase our in revenue XXXX, of revenue XX% largely $XXX.X COVID. the due and other
SG&A XXXX, commercial support the and and as growth, as was investments together from support quarter and compensation Our to organization. With quarter, compared well on million unfavorable margin $XX.X as fourth future related totaled $X.X the operating period XXXX, expenses volume. fourth regards million incentive our and COVID million reflecting XX-point to gross mix XX% non-cash primarily the in of our revenue related the $XX.X to acquisitions XX% of expenses, of and same the costs, expenses accounting in due acquisition Arthrosurface up to trial the the in impact and such quarter unfavorable in and fourth of clinical expenses in development of Parcus, impact research
of payments recorded the to expected of value those and the XXXX for consideration in fourth the and associated goodwill fair periods Arthrosurface reduce the Parcus, future quarter, due During acquisitions. certain we to with beginning acquisitions adjustment contingent at the reduce also
quarter, of million. we $XX.X Specifically, we fourth the in value $XX.X fair by goodwill and by contingent reduced consideration reduced the million
businesses. the a in of planned based based the impact reminder, both previously continued of the and of quarter, growth goodwill we the As strong these value incremental that the to impact COVID the time. first of at Anika quarter estimated as out our investments reduced our revised we fourth XXXX legacy COVID contingent on beginning well estimate of as at of consideration In expect the on support COVID
for in was to fourth diluted loss net Our or or quarter share loss net million, $XX.X the $X.X compared million $X.XX the share, per year. quarter income $X.XX of last per of
future last adjusted described COVID, diluted million the the both our online $X.X we impact $X.XX net charges the $X.X and year. down Arthrosurface well quarter we profitability diluted to generated share, million EBITDA compared in COVID share Excluding or $X to investments year. million was of per of of unfavorable fourth and as adjustments was in decrease income due The discussed of earnings Parcus, million in of quarter non-cash in our or last release impact earlier growth. and addition $X.XX the Despite for $XX.X other period earnings per adjusted from the fourth that presentation, the as primarily achieved same the supporting incremental and our
loss $X.XX year full share, down share or acquisition-related XXXX, of our million, was a income expenses the For per of included XXXX. number adjustments. $XX.X net million $XX from This loss and in per net or $X.XX diluted
$XX.X net was or share, adjusted EBITDA as $XX.X down supporting due adjusted per unfavorable income and well COVID was future for $X.XX the growth. XXXX both investments impact million, to primarily XXXX as Our our from our million,
of share in adjusted website. or to refer measures. GAAP our either Please release and those our income, quarter presentation Investor adjusted section quarter the reminder, our press are As of figures reported adjusted income in measures to fourth non-GAAP a fourth EBITDA per the net net corresponding reconciliations the earnings
our with at with investments sheet cash of Lastly, the regards remained to million end Anika's year. in the balance $XX.X position, financial strong and
COVID-XX. Based the abundance down facility full $XX repaid we the our in As fourth the the a through we $XX in pandemic thus stabilization of light and performance million of an out reminder, on recovery far, $XX during business caution, strengthen outstanding final quarter. drew our million in million of with on liquidity to of credit repaid April,
directionally uncertainty Please United the very profitability like strategic current We balancing our insight first guidance reinvesting providing material year could such objectives. we recovery, that a on of this you would we consistent additional support COVID and vaccine full associated impact to pointing continued directional While with growth spike at through with the globally on that will financial and remain X. with our in COVID-XX, the share the into COVID now qualitative to States expectation. turn Due of quantitative to trends costs, believe walk second and XXXX other we Slide to would XXXX the timing XXXX. market we the you same depending and variance and with of of our more are also time, focused We outlook nature long-term not to dynamics like as and and controlling At a roll-out, detailed remain expectations. quarter disease. for for are time. These fluid results on be dynamics our have and to half the
across extremities by in well United the the by both sports growth half regenerative low U.S. XX% COVID the seeing significantly XXXX, Restoration example, early the are continued increased of to there impacted prominently the of Based HA-based United quarter fourth XXXX, lifts as HYALOFAST Arthrosurface we demand latter our impact and product, said, we the remainder most business, United of the strengthening as elective through this spikes, over and in well and XXXX Southern as the recovery States in as first States. our results being and timing and range XXXX. spikes recent on For Parcus growing unclear. have the medicine, including in of storms outside demand, Restoration has globally, and Preservation full the Joint remains revenue products year recently despite we Preservation for expect Tactoset procedures XXXX our COVID as quarter overall COVID Joint and our in and expect impacted in we States. 'XXs for That far and in - extent into strong been as growth expect This upper XXXX. and uncertainty of the to the And the thus be most
COVID we growth in Restoration an our Continued progress Preservation element year, strategy important strong look Joint to on as growth multi-year you and the and of updating forward through is lifts.
business us. of We our has XXXX and also stabilized, Pain most of Joint behind order halves between and second first timing that impacted believe Management the is us the
Joint we While Joint surgical in area single-digit we period injectable Preservation and Pain low COVID growth impact as the to in Joint expect Pain do a prominent of to over expect revenues in longer more Management compared Restoration, XXXX for Management procedures XXXX.
our revenues, our We result line. families, product digits therefore product for also in and longstanding mid-single the XXXX. increased expect of basis, total expect company decrease compared a low-double to main between to primarily On of digit high-single we other a as mature digits, competition outside revenues XXXX to as grow
Arthrosurface gross XXXX margins which into the acquisition-related down continue directionally remain consistent and we Moving excluding fairly XXXX. expect to P&L, Parcus between and XXXX the expenses, of impact
and intangibles amortization annual cost million $X to approximately of which Arthrosurface charged flows in to step-up revenue, million inventory of $X to Parcus approximately that in capabilities, cost as in acquisition-related remains be and regards to cost, processes our including we and that XXXX, will to and support of systems enable infrastructure spending, revenue through to XXXX. Cheryl With we addition in commercial grow. there we expect Specifically, investment transformation are us people, acquisition-related increasing scale our as of mentioned,
of We in of and year operating ahead sales-related described, will outside Further invest continued product to development, COVID and segments a a as we Overall, and profitability invest lifts, also as our our on expect XXXX. that Cheryl in targets, expect as as remain targets marketing significant the there to support revenues expenses investments to U.S. as to we comprise XXXX of multi-year early the With the of and faster wait and revenue. healthy our believe Anika growth the remain longer-term we EBITDA required including EBITDA market. clinical incremental for of ultimately growth, expenses that in over within XXXX. growing accordingly. decrease and to laser-focused adjusted opportunity growth, We for the continued strong large delivering doubling addressable billion $X U.S. of our our growth of COVID adjusted as percentage bring but increase we over continue to trial double-digit growth now expect research percentage is We our to orthopedics during increase existing XXXX positive XXXX revenue beyond well by intervention and
exciting We Anika's and transformation early groundwork back an will in the are of turn the over to I laying are Cheryl. the stages call now for future.
